These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31919775)

  • 1. Thyroid eye disease: current and potential medical management.
    Pouso-Diz JM; Abalo-Lojo JM; Gonzalez F
    Int Ophthalmol; 2020 Apr; 40(4):1035-1048. PubMed ID: 31919775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in steroid sparing medical management of active thyroid eye disease.
    Liou VD; Yoon MK
    Semin Ophthalmol; 2020 May; 35(4):216-223. PubMed ID: 32684074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and thyroid eye disease (TED): a systematic review.
    Malboosbaf R; Maghsoomi Z; Emami Z; Khamseh ME; Azizi F
    Endocrine; 2024 Jul; 85(1):11-17. PubMed ID: 38194219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
    Strianese D
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the management of thyroid eye diseases: An overview.
    Kumari R; Chandra Saha B
    Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
    Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
    Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
    Krassas GE; Gogakos A
    J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
    Krassas GE
    Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.
    Ueland HO; Neset MT; Methlie P; Ueland GÅ; Pakdel F; Rødahl E
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S19-S28. PubMed ID: 38054982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on 'Acute thyroid eye disease (TED): principles of medical and surgical management'.
    Litwin AS; Malhotra R
    Eye (Lond); 2014 May; 28(5):632. PubMed ID: 24603423
    [No Abstract]   [Full Text] [Related]  

  • 19. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.
    Bufalo NE; Dos Santos RB; Marcello MA; Piai RP; Secolin R; Romaldini JH; Ward LS
    J Endocrinol Invest; 2015 May; 38(5):555-61. PubMed ID: 25543543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease-Methodology and Clinical Applications.
    Diana T; Kahaly GJ
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S13-S19. PubMed ID: 29771755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.